Outlook Therapeutics' wet AMD therapy study results validates expectations, looks forward to Phase 3

Outlook Therapeutics' wet AMD therapy study results validates expectations, looks forward to Phase 3Подробнее

Outlook Therapeutics submits BLA to FDA for its investigational therapy to treat wet AMDПодробнее

“The Buzz'' Show: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Trial for Wet AMD TreatmentПодробнее

Part 2: Long-term Outcomes in the Treatment of Wet AMDПодробнее

Age-Related Macular Degeneration and Diabetes-Related Eye Diseases Series ft. Outlook TherapeuticsПодробнее

Outlook Therapeutics | C. Russell Trenary III - President & CEOПодробнее

OTLK STOCK IS EXPLODING - OUTLOOK ANNOUNCES POSITIVE PHASE 3 TRIAL RESULTS WHICH EXCITED THE MARKETПодробнее

“The Buzz'' Show: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Trial for Wet AMD TreatmentПодробнее

Outlook Therapeutics reaches another milestone with FDA acceptance of wet AMD applicationПодробнее

OTLK Stock OVER $6?! | Outlook Therapeutics First FDA Approved Blindness Cure?!Подробнее

AMD Expert Insights - Mike HorlerПодробнее

Urgency of Retinal ReferralsПодробнее

INVESTOR NEWS || New WET AMD drug under review by the FDA | Whats you need to know before 29AugПодробнее

The Ultragenyx Phase 2 and 3 Orbit StudyПодробнее

OPTIC post hoc analyses: OPTIC and PACE comparison & impact of mutations on ponatinib starting doseПодробнее

Positive Study Results for Acute Optic Neuritis MedicationПодробнее

Advances in AMD Research: What’s in the pipeline - Christina Flaxel, M.D.Подробнее

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVOПодробнее

AAO 2021 Late Breakers: DAVIO and NORSE-2Подробнее

Dr. Daniel Miller - Wet AMD - Retina StudyПодробнее